[Guillain-Barre syndrome associated with COVID-19]. / Sindrom Giiena­Barre, assotsiirovannyi s COVID-19.

This paper reports two cases of Guillain-Barre syndrome associated with coronavirus infection COVID-19. The clinical symptoms and neurological status of patients, the data of the additional examination and the features of the prescribed therapy are described in detail. The issue of the tropicity of the SARS-CoV-2 virus to human nervous tissue and its possible ways of affecting the peripheral nervous system is discussed.

[Rehabilitation of patients with chronic low back pain]. / Reabilitatsiya patsientov s khronicheskoi bol'yu v nizhnei chasti spiny.

Low back pain occupies one of the leading places among pain syndromes and is an urgent medical, social, and economic problem of our time. A review of modern domestic and foreign literature data on the features of diagnosis, treatment and rehabilitation of chronic dorsalgia in patients with comorbid pathology was carried out. The article reflects the main etiological factors, describes the types of back pain: non-specific (musculoskeletal), radiculopathy, pain associated with potentially dangerous diseases, in addition, issues of the pathogenesis of pain syndromes are highlighted with an indication of nociceptive, neuropathic, psychogenic components. The most common comorbidity in patients with chronic pain in the lower back is characterized. Diagnostic algorithms for the problem under study, measures of drug and non-drug therapy, the possibility of practicing yoga for chronic lower back pain from the standpoint of evidence-based medicine are considered. It was stated that the treatment of chronic pain in the lower back should be individual, with an impact on different links in the pathogenesis of the pathological process. At the same time, the practice of yoga allows you to comprehensively influence the body at various levels: physical, psychological, mental. However, further research is required in this area.

[Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke]. / Issledovanie effektivnosti i bezopasnosti posledovatel'nogo primeneniya preparatov Meksidol i Meksidol Forte 250 pri lechenii bol'nykh s ostrym ishemicheskim insul'tom.

OBJECTIVE: To evaluate the effect of Mexidol on the recovery of cognitive functions in patients after ischemic stroke (IS). MATERIAL AND METHODS: We examined 70 patients with acute IS, who were randomized into 2 groups by random sampling; The 1st group consisted of patients who, against the background of the main standard therapy for 14 days, received Mexidol intravenously, 500 mg 1 time per day, followed by oral administration of Mexidol FORTE 250, 750 mg per day for 60 days (40 patients; 28 men, 12 women). Group 2 consisted of 30 patients (21 men, 9 women) who received only standard therapy. RESULTS: Baseline scores on the MoCA and MMSE scales did not differ between the two groups. Retesting showed that the improvement on these scales was statistically more significant in the 1st group. The analysis of indicators of the evoked potential P300 confirmed a more pronounced positive trend in the 1st group (p<0.01). CONCLUSION: The use of sequential therapy with Mexidol is accompanied by a more complete recovery of cognitive functions in patients who have undergone IS.

[Cytoflavin in the complex therapy of multiple sclerosis]. / Tsitoflavin v kompleksnoi terapii rasseiannogo skleroza.

AIM: To evaluate the efficacy of cytoflavin inclusion in the complex therapy of patients with multiple sclerosis in the remitting form during the period of exacerbation. MATERIAL AND METHODS: The results of therapy of 41 patients matched for sex, age and parameters of clinical and laboratory data were analyzed. Depending on the scheme of therapy, patients were divided into 2 groups: patients of the first group (n=22) received hormonal therapy with methylprednisolone. Patients of group II (n=19) received cytoflavin. The efficacy of treatment was assessed by a set of clinical and laboratory indicators in dynamics - before the start of therapy, with a 10-day interval and after treatment. The neurological status was assessed with the most commonly used scales (functional system scale (FS), EDSS scale), also neuroimaging data were assessed. RESULTS AND CONCLUSION: The inclusion of cytoflavin as an antioxidant and neuroprotective agent in the therapy of patients with multiple sclerosis in the acute phase increased the efficacy of basic (hormonal) therapy, which is manifested in a significant decrease in the severity of neurologic symptoms and visual system disorders and fewer cases of non-response to treatment.

[Neurotrauma as a factor of epileptogenesis]. / Travma golovnogo mozga kak faktor épileptogeneza.

The presented article deals with traumatic brain injury, which can cause convulsive seizures with the subsequent development of epilepsy, which is especially characteristic of young people. The problems of classification of posttraumatic epileptic seizures, development of their mechanisms, characteristics of diagnosis, as well as the stages of epileptogenesis leading to the development of traumatic epilepsy are considered. The variants of therapy are given in view of traumatic brain injury. It is noted that the use of electrical stimulation during individual phases of paroxysmal oscillations can be an effective method in preventing the development of homeostatic plasticity that is involved in the development of epileptogenesis.